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Jesús M Hernández-Rivas Secondary myeloid neoplasias are a heterogeneous group of diseases characterized
by the proliferation of myeloid cells; they were recently recognized by the World Health
Organization (WHO) as an entity. The wide use of chemotherapy and better diagnosis of
hematological malignancies has caused a growth in the number of secondary malignancies.
Most of them are myeloid: a) myelodysplastic syndromes (MDS), a heterogeneous group
of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis
and dysplastic changes in bone marrow and peripheral blood with the risk of transformation
to acute myeloid leukemia (AML) or b) sometimes the previous disease directly evolves
to an overt AML. Usually the prognosis of patients with a secondary myeloid neoplasia
is poor, especially when the previous disease is a MDS. However, patients may achieve
a complete response. In this situation, progenitor stem cell transplantation is the best
therapy.
Cytogenetic analysis still plays a pivotal role in the diagnosis of hematological
diseases. Cytogenetics and mutational analysis are the main prognostic tools in both
AML and MDS. For this reason, cytogenetic studies are critical in the correct management
of these diseases. There are several cytogenetic abnormalities associated with better
prognosis, such as translocations involving core binding factors in AML patients, and
losses in 20q, 5q or chromosome Y in MDS. In contrast, many others abnormalities are
associated with dismal prognoses, such as the presence of a complex karyotype,
abnormalities of either chromosome 3 or chromosome 7 and, in case of AML, the loss of
the long arm of chromosome 5.
All of these abnormalities are included in the new staging system for MDS (IPSS-2).
Recently new data regarding the presence of abnormalities in chromosome 7 in primary
MDS showed that the presence of a partial deletion of the long arm of this chromosome
(7q-) is associated with a better prognosis than monosomy 7.(1) This abnormality is a
common event in secondary MDS and AML and the potential value of this observation
in secondary MDS should be addressed. In this issue of the Revista Brasileira de
Hematologia e Hemoterapia a new observation highlighted the importance of performing
cytogenetic studies in secondary MDS.(2)
Over recent years, the wide use of microarrays and, more recently, the possibility of
sequencing the human genome have provided new insights into knowledge of the molecular
mechanisms involved in MDS and AML. Analysis of the gene expression profile by means
of microarray technology demonstrated the presence of new pathways involved in the
pathogenesis of these disorders, although studies focusing on secondary myeloid diseases
are lacking.(3) Since the sequencing of the entire genome of the first hematological malignancy,
a patient with AML,(4) several papers have shown the interest of the detection of new genes
involved in these diseases.(5) Some of these papers have also described the involvement of
new functions involved in myeloid diseases such as the spliceosome mechanism that
could play an essential role in the genesis of both MDS and AML.(6) Therefore, near future
investigations should provide more information of the genes involved in secondary myeloid
diseases. The challenges will be to understand these genes which are thought to be drivers
in the genesis of secondary myeloid neoplasias and, more importantly, to identify new
therapeutic targets.
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Iron is an essential micronutrient, as it is required for an adequate erythropoietic
function, oxidative metabolism and cellular immune response. In the human body, iron
metabolism pathways include absorption from food, distribution to target cells, storage
and recycling.(1) Dietary iron is found as heme (10%) and non-heme (ionic, 90%) forms;
absorption occurs at the apical surface of duodenal enterocytes via different, tightly
regulated, mechanisms with absorption balancing losses (1-2 mg/day) as no active iron
excretory mechanisms exist. Dietary non-heme iron primarily exists in an oxidized (Fe3+) form
that is not bioavailable and must first be reduced to the Fe2+ form by a ferrireductase
enzyme, that uses vitamin C as a coenzyme, before being transported across the intestinal
epithelium by the divalent metal transporter 1 (DMT1). Heme iron is transported into the
enterocyte by a putative heme carrier protein 1 and metabolized by heme oxygenase to
release Fe2+, which enters a common pathway with dietary non-heme iron before it leaves
the enterocyte. Iron is exported by ferroportin 1 (the only putative iron exporter) across the
basolateral membrane of the enterocyte into the circulation (absorbed iron) where it binds
to transferrin and is transported to sites of use and storage. Transferrin-bound iron enters
target cells – mainly erythroid cells, but also immune, muscle and liver cells – through a
process of receptor-mediated endocytosis.
Erythrocytes contain up to 65-70% of body iron. Senescent erythrocytes undergo
phagocytosis by macrophages of the reticuloendothelial system, heme is metabolized by
heme-oxygenase and the released iron stored as ferritin. Iron will later be exported from
macrophages to transferrin, a process accomplished primarily by ferroportin 1, the same
iron-export protein expressed in the duodenal enterocyte and in ceruloplasmin. The amount
of iron required for a daily production of 300 billion red blood cells (20-30 mg) is provided
mostly by macrophage iron recycling. Thus, this internal turnover of iron is essential to
meet the requirements of erythropoiesis.
Hepcidin, synthesized by hepatocytes in response to low iron levels, inflammation,
hypoxia and erythropoiesis, is the main iron homeostasis regulatory hormone. Hepcidin
binds ferroportin on enterocytes, macrophages and hepatocytes triggering its internalization
and lysosomal degradation. Therefore, increased hepcidin secretion may lead to iron
deficiency (ID) and anemia.(1)
As stated above, under physiological conditions, there is a balance between iron
absorption and iron loses in the human body. Thus, ID and iron deficiency anemia (IDA)
may result from the interplay of three distinct risk factors: increased iron requirements,
limited external supply and increased blood loss.(2) ID can be either absolute or functional.
In absolute ID, iron stores are depleted; in functional ID (FID), iron stores, although
replete, cannot be mobilized as fast as necessary from the macrophages of the
reticuloendothelial system to the bone marrow (treatment with erythropoiesis stimulating
agents and inflammation are the most common causes of FID). In chronic inflammation,
the excess of hepcidin decreases iron absorption and prevents iron recycling, resulting
in hypoferremia and iron restricted erythropoiesis, in despite of normal iron stores, and
finally anemia of chronic disease (ACD), which can further evolve to ACD plus true ID
(ACD + ID).
Investigation of ID in the clinical practice mostly relies on laboratory tests which fall
